Utility of emergent plain X‐ray for childhood acute leukemia with bone pain

2021 ◽  
Author(s):  
Ai Ito ◽  
Tomoo Osumi ◽  
Kentaro Fujimori ◽  
Daisuke Tomizawa ◽  
Motohiro Kato ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Bone Pain ◽  
X Ray ◽  
Childhood Acute Leukemia

scholarly journals BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 924
Author(s):  
Elena Zerkalenkova ◽  
Svetlana Lebedeva ◽  
Aleksandra Borkovskaia ◽  
Olga Soldatkina ◽  
Olga Plekhanova ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Residual Disease ◽  
Chromosomal Rearrangements ◽  
Strong Impact ◽  
Acute Leukemias ◽  
Dna And Rna ◽  
Targeted Ngs ◽  
Childhood Acute Leukemia ◽  
Next Generation Sequencing Ngs ◽  
The Given

Chromosomal rearrangements of the human KMT2A/MLL gene are associated with acute leukemias, especially in infants. KMT2A is rearranged with a big variety of partner genes and in multiple breakpoint locations. Detection of all types of KMT2A rearrangements is an essential part of acute leukemia initial diagnostics and follow-up, as it has a strong impact on the patients’ outcome. Due to their high heterogeneity, KMT2A rearrangements are most effectively uncovered by next-generation sequencing (NGS), which, however, requires a thorough prescreening by cytogenetics. Here, we aimed to characterize uncommon KMT2A rearrangements in childhood acute leukemia by conventional karyotyping, FISH, and targeted NGS on both DNA and RNA level with subsequent validation. As a result of this comprehensive approach, three novel KMT2A rearrangements were discovered: ins(X;11)(q26;q13q25)/KMT2A-BTK, t(10;11)(q22;q23.3)/KMT2A-NUTM2A, and inv(11)(q12.2q23.3)/KMT2A-PRPF19. These novel KMT2A-chimeric genes expand our knowledge of the mechanisms of KMT2A-associated leukemogenesis and allow tracing the dynamics of minimal residual disease in the given patients.

scholarly journals Sequential Oral Hydroxyurea and Intravenous Cytosine Arabinoside in Refractory Childhood Acute Leukemia

2008 ◽  
Vol 30 (5) ◽  
pp. 353-357 ◽  
Author(s):  
Ronald Dubowy ◽  
Michael Graham ◽  
Nasrollah Hakami ◽  
Morris Kletzel ◽  
Donald Mahoney ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Cytosine Arabinoside ◽  
Childhood Acute Leukemia

scholarly journals Benzene and childhood acute leukemia in Oklahoma

2017 ◽  
Vol 158 ◽  
pp. 167-173 ◽  
Author(s):  
Amanda E. Janitz ◽  
Janis E. Campbell ◽  
Sheryl Magzamen ◽  
Anne Pate ◽  
Julie A. Stoner ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Childhood Acute Leukemia

scholarly journals Acute leukemia of childhood: A single institution's experience

2005 ◽  
Vol 57 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Bojana Slavkovic ◽  
Marija Guc-Scekic ◽  
Gordana Bunjevacki ◽  
S. Djuricic ◽  
Aleksandra Krstic ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Acute Leukemia ◽  
Childhood Leukemia ◽  
Lymphoblastic Leukemia ◽  
Chromosomal Rearrangements ◽  
Age Distribution ◽  
Normal Karyotype ◽  
Mediterranean Countries ◽  
B Lineage ◽  
Childhood Acute Leukemia

The aim of this study was to investigate distribution of immunophenotypic and cytogenetic features of childhood acute leukemia (AL) in the cohort of 239 newly diagnosed patients registered at the leading pediatric oncohematology center in the country during a six-year period (1996-2002). With approximately 60-70% of all childhood AL cases in Serbia and Montenegro being diagnosed and treated in this institution the used data represent a valid research sample to draw conclusions for entire country. On the basis of five phenotypic markers, the distribution of immunological subtypes was as follows: 169 (70.7%) expressed B-cell marker CD19 (137 were CD10 positive and 32 CD10 negative), 37 (15.5%) belonged to T-lineage acute lymphoblastic leukemia (T-ALL) (cyCD3 positive), and 33 (13.8%) were acute myeloblastic leukemia (AML) (CD13 positive and/or CD33 positive in the absence of lymphoid-associated antigens). The ratio of males and females was 1.5:1. Most of the cases were between the ages of 2 and 4, and were predominantly B-lineage acute lymphoblastic leukemia (B-ALL) cases. Another peak of age distribution was observed at the age of 7. The frequency of T-ALL (18% of ALL) was similar to that reported for Mediterranean countries: France (19.4%), Greece (28.1%), Southern Italy (28.3%), and Bulgaria (28.0%). Cytogenetic analyses were performed in 193 patients: 164 ALL and 29 AML. Normal karyotype was found in 57% of ALL and in 55% of AML patients, while cytogenetic abnormalities including structural, numerical, and complex chromosomal rearrangements were found in 43% of ALL and in 45% of AML patients. Our results represent a contribution to epidemiological aspects of childhood leukemia studies.

scholarly journals Polymorphism of Biotransformation Genes and Risk of Relapse in Childhood Acute Leukemia

2009 ◽  
Vol 12 (1) ◽  
pp. 21-35 ◽  
Author(s):  
O Gra ◽  
Zh Kozhekbaeva ◽  
O Makarova ◽  
E Samochatova ◽  
T Nasedkina
Keyword(s):  
Bone Marrow ◽  
Acute Leukemia ◽  
Childhood Leukemia ◽  
Hematological Malignancy ◽  
Lymphoblastic Leukemia ◽  
Leukemia Relapse ◽  
Polymorphic Variants ◽  
Childhood Acute Leukemia ◽  
Primary Leukemia ◽  
Risk Of Relapse

Polymorphism of Biotransformation Genes and Risk of Relapse in Childhood Acute LeukemiaLeukemia is a hematological malignancy that involves bone marrow. Polymorphism of biotransformation genes plays an important role in primary childhood leukemia and affects the incidence and character of acute leukemia relapse. A biochip designed to assess some polymorphisms of biotransformation genes was used to determine the frequency of the polymorphic variants ofCYP1A1, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, CYP2C9, CYP2C19andNAT2in 332 children with acute lymphoblastic leukemia (ALL) and 71 children with acute myeloblastic leukemia (AML). TheCYP1A1 *1/*2A, GSTT1non null andGSTM1non null genotypes were more frequent in patients with primary leukemia than in relapse. Analysis of theNAT2genotype frequency revealed a characteristic genotype for each type of leukemia, which prevailed in patients with relapse: the genotype341C/-, 481T/-, 590G/G, 857G/Gprevailed in ALL patients with relapse, and the genotype341T/T, 481C/C, 590A/- in AML patients with relapse when compared with patients having primary ALL or AML, respectively. Thus, the polymorphisms ofCYP1A1, GSTT1, GSTM1andNAT2genes can be considered as markers for risk of relapse in childhood acute leukemia and can be used for the prognosis and individualization of standard therapy.

Sign in / Sign up

Export Citation Format

Share Document